Beijing, Sep 6 (EFE) .- China will soon begin clinical trials with the drug for covid-19 developed by the state pharmaceutical CNBG, based on the plasma of recovered patients and considered by the state press as the first d ‘this guy in the world.
‘Animal test results show that it can significantly alleviate the symptoms and damage caused by coronavirus. He has just received approval from the State Drug Administration and clinical research will begin soon, ”CNBG Vice President Zhu Jingjin said.
Through a message posted this Sunday on the Chinese social network’s WeChat account of the State Council’s Administration and Oversight Commission, Zhu detailed that ‘the plasma of patients recovered from covid (.. .) gives good results with critical and severe patients’ of covid-19.
According to the source, this type of treatment elicits a faster response for this type of at-risk patients.
However, Jiang Chulai, of Jilin University, clarified that ‘the actual effectiveness of a special drug remains dependent mainly on the results of clinical trials, rather than on the findings of the early stages’.
Another source also quoted by the state-run Global Times added that drugs serve to alleviate the effects of infection, but that prevention and vaccination remain the most effective ways to curb infections and their effects.
CNBG and its parent company, state-owned Sinopharm, have so far developed two vaccines for inactivated virus covid-19 that are being used in countries such as Brazil, Indonesia, the United Arab Emirates and China itself.
The latest data from China’s National Health Commission show that the Asian country has inoculated more than 2.1 billion doses of covid vaccines, many of them developed by CNBG and Sinopharm.
The company has also indicated that it is working on two vaccines for the covid of different technologies (one of them, messenger RNA, such as those of the American pharmaceutical companies Pfizer and Moderna) which, according to Zhu, have been shown to be effective against new strains of the SARs-CoV-2 coronavirus. EFE
jt / aa / mcd